イヌの実験的エンドトキシンショック時の 6-keto-PGF<SUB>1α</SUB> および Thromboxane B<SUB>2</SUB> に対するPAF拮抗薬(CV-3988)の効果

DOI Web Site Web Site PubMed 被引用文献2件 参考文献29件

書誌事項

タイトル別名
  • Effect of Platelet Activating Factor Antgaonist(CV-3988) on 6-keto-PGF1.ALPHA. and Thromoboxane B2 in Dogs with Experimental Endotoxin-Induced Shock.
  • イヌの実験的エンドトキシンショック時の6-keto-PGF1αおよびThromboxane B2に対するPAF拮抗薬(CV-3988)の効果〔英文〕
  • イヌ ノ ジッケンテキ エンドトキシン ショックジ ノ 6-keto-PGF1

この論文をさがす

抄録

The effect of CV-3988, a platelet activating factor antagonist, in the treatment of endotoxic shock was evaluated from the changes in plasma 6-keto-PGF1α and thromboxane B2 concentrations. The animals consisted of 10 beagle dogs anesthetized with pentobarbital sodium and divided into a treatment group (n=5) and a control group (n=5). Endotoxic shock was experimentally induced in both groups by intravenous administration of endotoxin (lipopolysaccharide, 3 mg/kg). The treatment group was intravenously given 10 mg/kg of CV-3988 for 10 min from immediately after endotoxin. Mean aortic pressure, cardiac output and urine volume were remarkably decreased after the administration of endotoxin to both groups. These parameters were higher after the administration of CV-3988, in the treatment group than in the control group. Furthermore, the increase in plasma 6-keto-PGF1α and thromboxane B2 concentrations was significantly inhibited. These results suggest the effectiveness of CV-3988 in the treatment of endotoxic shock.

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (29)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ